• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SASS6 促进肺腺癌肿瘤增殖，并与 TP53 和免疫浸润相关。

SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma.

机构信息

Department of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.

Department of Nephrology, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.

出版信息

Clin Exp Med. 2024 Oct 24;24(1):243. doi: 10.1007/s10238-024-01510-0.

DOI:10.1007/s10238-024-01510-0
PMID:39443355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11499408/
Abstract

The most common type of non-small cell lung cancer is lung adenocarcinoma (LUAD), which is characterized by high morbidity and poor survival. Up-regulation of SASS6 expression can lead to the progression of various malignant tumors. However, there are no relevant studies on the role of SASS6 in LUAD. SASS6 was highly expressed in most tumors, reflecting a good diagnostic value, and its overexpression in LUAD indicated discouraging overall prognosis. Functional enrichment analysis suggested that SASS6 was associated with cell cycle in LUAD. In addition, patients with high SASS6 expression had worse immune infiltration, but higher TMB and immune checkpoint, and higher sensitivity to multiple targeted drugs such as osimertinib. Cell experiments confirmed that knockdown of SASS6 could inhibit the viability of tumor cells.SASS6 has important value in the diagnosis of cancer. In particular, SASS6 is a crucial factor in the progression of LUAD, and has important clinical value, especially in the diagnosis, prognosis and treatment.

摘要

最常见的非小细胞肺癌类型是肺腺癌（LUAD），其发病率高，生存状况差。SASS6 表达上调可导致多种恶性肿瘤的进展。然而，目前尚无关于 SASS6 在 LUAD 中作用的相关研究。SASS6 在大多数肿瘤中高表达，反映了良好的诊断价值，其在 LUAD 中的过表达预示着整体预后不佳。功能富集分析表明，SASS6 与 LUAD 中的细胞周期有关。此外，SASS6 高表达的患者免疫浸润更差，但 TMB 和免疫检查点更高，对奥希替尼等多种靶向药物更敏感。细胞实验证实，敲低 SASS6 可抑制肿瘤细胞的活力。SASS6 在癌症诊断中具有重要价值。特别是，SASS6 是 LUAD 进展的关键因素，具有重要的临床价值，特别是在诊断、预后和治疗方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/3191d321df33/10238_2024_1510_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/d0766b7c70d8/10238_2024_1510_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/c3237f248125/10238_2024_1510_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/792abd8b42ff/10238_2024_1510_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/70c30d533288/10238_2024_1510_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/ac20210b5e11/10238_2024_1510_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/81edbd72c293/10238_2024_1510_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/95cd60f397a8/10238_2024_1510_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/dc158b17fedd/10238_2024_1510_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/d18b8312dc83/10238_2024_1510_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/1697f2ea6521/10238_2024_1510_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/3191d321df33/10238_2024_1510_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/d0766b7c70d8/10238_2024_1510_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/c3237f248125/10238_2024_1510_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/792abd8b42ff/10238_2024_1510_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/70c30d533288/10238_2024_1510_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/ac20210b5e11/10238_2024_1510_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/81edbd72c293/10238_2024_1510_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/95cd60f397a8/10238_2024_1510_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/dc158b17fedd/10238_2024_1510_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/d18b8312dc83/10238_2024_1510_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/1697f2ea6521/10238_2024_1510_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/139b/11499408/3191d321df33/10238_2024_1510_Fig11_HTML.jpg

相似文献

1
SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma.SASS6 促进肺腺癌肿瘤增殖，并与 TP53 和免疫浸润相关。
Clin Exp Med. 2024 Oct 24;24(1):243. doi: 10.1007/s10238-024-01510-0.
2
Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma.与PRDX1相关的恶性特征与EGFR突变型肺腺癌的奥希替尼敏感性相关。
Int J Med Sci. 2025 Mar 31;22(9):2040-2058. doi: 10.7150/ijms.107255. eCollection 2025.
3
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.RPL22L1 是肺腺癌预后和免疫浸润的新型生物标志物，通过抑制 MDM2/P53 信号通路促进 LUAD 细胞的生长和转移。
Aging (Albany NY). 2024 Aug 28;16(17):12392-12413. doi: 10.18632/aging.206096.
4
The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.EMG1 在肺腺癌进展中的作用：对预后和免疫细胞浸润的影响。
Int Immunopharmacol. 2024 Sep 10;138:112553. doi: 10.1016/j.intimp.2024.112553. Epub 2024 Jun 28.
5
DEPDC1B is a Novel Direct Target of B-Myb and Contributes to Malignant Progression and Immune Infiltration in Lung Adenocarcinoma.DEPDC1B是B-Myb的一个新的直接靶点，促进肺腺癌的恶性进展和免疫浸润。
Front Biosci (Landmark Ed). 2024 May 27;29(6):204. doi: 10.31083/j.fbl2906204.
6
Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma.CDCA8 过表达预示肺腺癌不良预后和药物耐药。
BMC Med Genomics. 2024 Nov 8;17(1):265. doi: 10.1186/s12920-024-02019-x.
7
Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.BCCIP 的过表达预示着不良的预后，并促进肺腺癌的增殖和迁移。
Thorac Cancer. 2021 Sep;12(17):2324-2338. doi: 10.1111/1759-7714.14073. Epub 2021 Jul 23.
8
SASS6 promotes proliferation of esophageal squamous carcinoma cells by inhibiting the p53 signaling pathway.SASS6通过抑制p53信号通路促进食管鳞状癌细胞的增殖。
Carcinogenesis. 2021 Feb 25;42(2):254-262. doi: 10.1093/carcin/bgaa067.
9
Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.早期肺腺癌中与 TP53 相关的免疫景观和有前途的免疫预后模型。
Cancer Med. 2021 Feb;10(3):806-823. doi: 10.1002/cam4.3655. Epub 2020 Dec 12.
10
DCUN1D5 is a prognostic biomarker and correlated immune infiltrates and glycolysis in lung adenocarcinoma.DCUN1D5是一种预后生物标志物，与肺腺癌中的免疫浸润和糖酵解相关。
Sci Rep. 2025 Jan 2;15(1):403. doi: 10.1038/s41598-024-84539-1.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Drugging p53 in cancer: one protein, many targets.在癌症中靶向 p53：一种蛋白，多个靶点。
Nat Rev Drug Discov. 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10.
3
The cell cycle, cancer development and therapy.细胞周期、癌症发生和治疗。
Mol Biol Rep. 2022 Nov;49(11):10875-10883. doi: 10.1007/s11033-022-07788-1. Epub 2022 Aug 5.
4
Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox.肿瘤中的细胞毒性 CD4 T 细胞：扩展免疫效应工具盒。
Immunity. 2021 Dec 14;54(12):2701-2711. doi: 10.1016/j.immuni.2021.11.015.
5
Tumor-Microenvironment-Activated Reactive Oxygen Species Amplifier for Enzymatic Cascade Cancer Starvation/Chemodynamic /Immunotherapy.用于酶促级联癌症饥饿/化学动力学/免疫治疗的肿瘤微环境激活活性氧放大器
Adv Mater. 2022 Jan;34(4):e2106010. doi: 10.1002/adma.202106010. Epub 2021 Nov 28.
6
Savolitinib: First Approval.赛沃替尼：批准上市。
Drugs. 2021 Sep;81(14):1665-1670. doi: 10.1007/s40265-021-01584-0.
7
Cell cycle on the crossroad of tumorigenesis and cancer therapy.细胞周期在肿瘤发生和癌症治疗的十字路口。
Trends Cell Biol. 2022 Jan;32(1):30-44. doi: 10.1016/j.tcb.2021.07.001. Epub 2021 Jul 22.
8
Lung cancer.肺癌。
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
9
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.I 期-III 期非转移性非小细胞肺癌的全身治疗演变。
Nat Rev Clin Oncol. 2021 Sep;18(9):547-557. doi: 10.1038/s41571-021-00501-4. Epub 2021 Apr 28.
10
Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.敲低 SASS6 可通过将细胞周期阻滞在 G2/M 期来减少 MDA-MB-231 三阴性乳腺癌细胞的生长。
Oncol Rep. 2021 Jun;45(6). doi: 10.3892/or.2021.8052. Epub 2021 Apr 28.